Результаты поиска

Каннабиноиды в раке: Молекулярные механизмы смерти клеток и возможности перевода.

Каннабиноиды представляют собой терпенофенолические соединения, полученные из Cannabis sativa L., которые осуществляют широкий спектр биологической и фармакологической деятельности. Растущие данные свидетельствуют об их потенциале как модуляторов развития рака, особенно посредством подавления роста клеток опухоли, ангиогенеза и метастаза в различных моделях опухоли. В настоящем обзоре содержится всеобъемлющий обзор молекулярных механизмов, с помощью которых природные и синтетические каннабиноиды вызывают регулируемую смерть раковых клеток. Текущие данные свидетельствуют о том, что каннабиноиды

Совпадение в полном тексте источника
… THC tetrahydrocannabinol; CBD cannabidiol; CBN cannabinol; CBG cannabigerol; CBC cannabichromene. The anticancer activity of cannabinoids was discovered in 1975 by Munson et al. [ 19 ]. … CBC cannabichromene; CBD cannabidiol; CBG cannabigerol; CBN cannabinol; THC tetrahydrocannabinol. …

Cannabis, One Health, and Veterinary Medicine: Cannabinoids' Role in Public Health, Food Safety, and Translational Medicine.

Public health is connected to cannabis with regard to food, animal feed (feed), and pharmaceuticals. Therefore, the use of phytocannabinoids should be examined from a One Health perspective. Current knowledge on medical cannabis treatment (MCT) does not address sufficiently diseases which are of epidemiological and of zoonotic concern. The use of cannabinoids in veterinary medicine is illegal in most countries, mostly due to lack of evidence-based medicine. To answer the growing need of scientific evidence-based applicable medicine in both human and veterinary medicine, a new approach for the

Совпадение в полном тексте источника
… A second approach would be to amend the criminal law and legalize cannabinoids, or at least cannabidiol (CBD) without restrictions. … Available at: https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd . 35. US Food & Drug Administration. FDA Regulation of Cannabis and Cannabis-Derived Products Including Cannabidiol. …

MCPB-21 targets glycogenin-2 to regulate fatty acid oxidation and promote ferroptosis of breast cancer.

This study systematically evaluated the anti-breast cancer potential and mechanisms of the cannabidiol (CBD) derivative MCPB-21. The structure of MCPB-21 was confirmed by nuclear magnetic resonance (NMR). The study analyzed differentially expressed genes associated with breast cancer using public databases and verified the binding affinity of MCPB-21 to glycogenin-2 (GYG2) through molecular docking. Additionally, the effects of MCPB-21 on apoptosis, invasion capacity, and lipid metabolism were evaluated in MDA-MB-231 and MCF-7 breast cancer cells using flow cytometry, Transwell invasion assays…

Effects of five cannabis oils with different CBD: THC ratios and terpenes on hypertension, dyslipidemia, hepatic steatosis, oxidative stress, and CB1 receptor in an experimental model.

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a common liver disorder caused by oxidative stress and dysregulation of lipid metabolism. The endocannabinoid system (ECS), particularly the type 1 cannabinoid (CB1) receptor, plays a crucial role in NAFLD progression. Cannabinoids, such as cannabidiol (CBD) and tetrahydrocannabinol (THC), along with terpenes, such as beta-myrcene and d-limonene, have shown potential therapeutic effects on liver health, particularly in reducing oxidative stress and modulating lipid metabolism. This study aimed to analyse the effects of five cannabis oils…

Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study).

BACKGROUND: The approval of Sativex for the management of multiple sclerosis (MS) spasticity opened a new opportunity to many patients. In Italy, the healthcare payer can be fully reimbursed by the involved pharma company with the cost of treatment for patients not responding after a 4 week (28 days) trial period (Payment by Results, PbR), and 50% reimbursed with the cost of 6 weeks (42 days) treatment for other patients discontinuing (Cost Sharing, CS). The aim of our study was to describe the Sativex discontinuation profile from a large population of spasticity treated Italian MS patients.

Cannabinoids Used for Medical Purposes in Children and Adolescents: A Systematic Review and Meta-Analysis.

IMPORTANCE: Cannabinoids are increasingly used for medical purposes in children. Evidence of the safety of cannabinoids in this context is s … other 12 trials (52.2%) included children, adolescents, and adults. Interventions included purified cannabidiol (11 [47.8%]), nabilone (4 [17.4%]), tetrahydrocannabinol (3 [13.0%]), cannabis herbal extract (3 [13.0%]), and dexanabinol (2 [8.7%]). The most common indications were epilepsy (9 [39.1%]) and chemotherapy-induced nausea and vomiting (7 [30.4%]). Co …

Качество жизни пациентов, получающих лекарственный каннабис: систематический обзор и метаанализ результатов первичных исследований 2015-2025.

ЦЕЛЬ: Глобальное бремя хронических заболеваний является значительным. Лекарственный каннабис (МК) является законным вариантом лечения пациентов с хроническими заболеваниями в некоторых странах. Качество жизни, связанное со здоровьем, является важным результатом, о котором сообщают пациенты, во всех хронических заболеваниях. Мы поставили перед собой цель определить, каким образом исследования в области медикаментозной терапии оправдывают, измеряют и сообщают о HRQL, а также оценить имеющиеся данные по HRQL после лечения МЦ. МЕТОДЫ: Систематический обзор поиска AMED, Medline, Web of Science, Sco

Совпадение в полном тексте источника
… The identification of cannabinoids, cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC), as analgesics in 1940 ignited interest in using a cannabis-based medicine as adjunctive treatment for the symptomatic relief of chronic pain [ 2 ]. … Tetrahydrocannabinol: Cannabidiol oromucosal spray for multiple sclerosis-related resistant spasticity in daily practice. European Neurology , 76 (5–6), 216–226. 10.1159/000449413 27732980 10.1159/000449413 44. …

Use of Cannabis and Cannabinoids for Treatment of Cancer.

The endocannabinoid system (ECS) is an ancient homeostasis mechanism operating from embryonic stages to adulthood. It controls the growth and development of many cells and cell lineages. Dysregulation of the components of the ECS may result in uncontrolled proliferation, adhesion, invasion, inhibition of apoptosis and increased vascularization, leading to the development of various malignancies. Cancer is the disease of uncontrolled cell division. In this review, we will discuss whether the changes to the ECS are a cause or a consequence of malignization and whether different tissues react dif

Совпадение в полном тексте источника
… In contrast, cannabidiol (CBD) has a very weak affinity for CB2 or CB1, although it may work as a negative allosteric regulator of these receptors [ 22 ], modulating THC activity. … Cannabidiol is a negative allosteric modulator of the cannabinoid CB 1 receptor J. Cereb. Blood Flow Metab. 2015 172 4790 4805 10.1111/bph.13250 PMC4621983 26218440 23. Burstein S. Cannabidiol (CBD) and its analogs: A review of their effects on inflammation Bioorganic Med. …

The Role of Cannabinoids in Advancing Cancer Treatment: Insights from Evidence-Based Medicine.

Purpose of reviewThis document critically examines the role of cannabinoids in cancer care during an era marked by rapid advancements in oncology and changing perceptions on cannabis. It traces the historical context of cannabis in medicinal use, navigating its journey from widespread acceptance, subsequent criminalization, to its resurgence in modern therapeutic applications, particularly within the framework of Evidence-Based Medicine (EBM).Recent findingsAnchored in EBM principles, this study synthesizes current research from clinical trials, systematic reviews, and meta-analyses to evaluat

Совпадение в полном тексте источника
… These include primarily Δ9-THC and cannabidiol (CBD), along with others such as cannabigerol, cannabichromene, cannabidivarin, and tetrahydrocannabivarin [ 3 ]. … The recent MedCan1-CBD phase IIb study further supported this, finding that cannabidiol oil does not decrease opioid use in cancer patients [ 44 ]. …

THC:CBD Observational Study Data: Evolution of Resistant MS Spasticity and Associated Symptoms.

BACKGROUND: The prospective observational MObility ImproVEment (MOVE) 2 study is collecting real-life clinical outcomes data on patients with treatment-resistant multiple sclerosis (MS) spasticity treated with THC:CBD oromucosal spray in routine clinical practice. The MOVE 2 study has been ongoing in Italy, involving more than 30 MS centres across the country, since 2013. METHODS: Web-based real-time data collection techniques are combined with traditional patients' diaries to capture a wide spectrum of outcomes associated with this innovative cannabis-based medication. After surpassing the r

Anti-Cancer Potential of Cannabinoids, Terpenes, and Flavonoids Present in Cannabis.

In recent years, and even more since its legalization in several jurisdictions, cannabis and the endocannabinoid system have received an increasing amount of interest related to their potential exploitation in clinical settings. Cannabinoids have been suggested and shown to be effective in the treatment of various conditions. In cancer, the endocannabinoid system is altered in numerous types of tumours and can relate to cancer prognosis and disease outcome. Additionally, cannabinoids display anticancer effects in several models by suppressing the proliferation, migration and/or invasion of can

Совпадение в полном тексте источника
… Cannabidiol (CBD) Cannabidiol (CBD) is one of the major and most extensively researched phytocannabinoids present in cannabis species. Cannabidiol binds to a large array of physiological targets within the body’s endocannabinoid system. … Cannabidiol is non-intoxicating, which is why its potential as a therapeutic agent is more appealing than some other cannabinoids that do possess psychoactive effects, like THC. To date, there are many studies surrounding the anti-cancer potential of cannabidiol. …

Therapeutic Potential of Cannabinoids on Tumor Microenvironment: A Molecular Switch in Neoplasia Transformation.

The efficacy of chemotherapy depends on the tumor microenvironment. This microenvironment consists of a complex cellular network that can exert both stimulatory and inhibitory effects on tumor genesis. Given the increasing interest in the effectiveness of cannabis, cannabinoids have gained much attention as a potential chemotherapy drug. Cannabinoids are a group of marker compounds found in Cannabis sativa L., more commonly known as marijuana, a psychoactive drug used since ancient times for pain management. Although the anticancer potential of C. sativa, has been recognized previously, increa

Совпадение в полном тексте источника
… Cannabidiol as a novel therapeutic for immune modulation. ImmunoTargets Ther. 2020;9:131-140. 29. Seltzer ES, Watters AK, MacKenzie D, Jr, Granat LM, Zhang D. Cannabidiol (CBD) as a promising anti-cancer drug. Cancers. 2020;12:3203. 30. Lowin T, Straub RH. … Cannabidiol, a non-psychoactive cannabinoid compound, inhibits proliferation and invasion in U87-MG and T98G glioma cells through a multitarget effect. PLoS One. 2013;8:e76918. 80. …

New Avenues and Major Achievements in Phytocompounds Research for Glioblastoma Therapy.

Phytocompounds have been evaluated for their anti-glioblastoma actions for decades, with promising results from preclinical studies but only limited translation into clinics. Indeed, by targeting multiple signaling pathways deregulated in cancer, they often show high efficacy in the in vitro studies, but their poor bioavailability, low tumor accumulation, and rapid clearance compromise their efficacy in vivo. Here, we present the new avenues in phytocompound research for the improvement of glioblastoma therapy, including the ways to enhance the response to temozolomide using phytochemicals, th

Совпадение в полном тексте источника
… Compound/Product | ClinicalTrials.gov ID | Description | Study Type/Phase | Status Cannabidiol | NCT05753007 | A Clinical Trial of a Hemp-Derived, High-Cannabidiol Product for Anxiety in Glioblastoma Patients | Phase 2 | Not yet recruiting NCT03607643 | A Study of the Efficacy of Cannabidiol in Patients … Cannabidiol Μay Prolong Survival in Patients with Glioblastoma Multiforme. Cancer Diagn. Progn. 2021;1:77–82. doi: 10.21873/cdp.10011. 114. Rybarczyk A., Majchrzak-Celińska A., Krajka-Kuźniak V. The Application of Cannabidiol in the Treatment of Glioblastoma. Acta Pol. Pharm. …

Последствия злоупотребления наркотиками для путей ферроптоза: потенциальные терапевтические цели для расстройств, связанных с потреблением психоактивных веществ.

Серьезными проблемами в области здравоохранения во всем мире, особенно в развитых странах, по-прежнему являются расстройства, связанные с потреблением психоактивных веществ. Для ОСВ характерна устойчивая нейроинфламмация и синаптическая дисфункция мозга. Несмотря на десятилетия интенсивного расследования, детальные механизмы, лежащие в основе ВСГ, по-прежнему остаются иллюзорными. Ферроптоз — это высокорегулируемый процесс смерти клеток, на который сильно влияют метаболизм железа, пероксидация липидов, производство реактивных видов кислорода (РОС) и антиоксидантные системы. Он был связан с мно

Совпадение в полном тексте источника
… Neuroprotective effect of cannabidiol against hydrogen peroxide in hippocampal neuron culture. Cannabis Cannabinoid. Res. 6, 40–47. doi: 10.1089/can.2019.0102 Klimiuk M., Jefimow M., Kletkiewicz H. (2026). … Cannabidiol attenuates OGD/R-induced damage by enhancing mitochondrial bioenergetics and modulating glucose metabolism via pentose-phosphate pathway in hippocampal neurons. Redox. …

A role for the putative cannabinoid receptor GPR55 in the islets of Langerhans.

The cannabinoid CB1 receptor is a well-known player in energy homeostasis and its specific antagonism has been used in clinical practice for the treatment of obesity. The G protein-coupled receptor GPR55 has been recently proposed as a new cannabinoid receptor and, by contrast, its pharmacology is still enigmatic and its physiological role is largely unexplored, with no reports investigating its putative role in metabolism. Thus, we aim to investigate in rats the presence, distribution and putative physiological role of GPR55 in a key metabolic tissue, the endocrine pancreas. We found high Gpr

Complementary and alternative therapies in the palliative setting.

Complementary and alternative medicine (CAM) encompasses a wide range of medication, herbal, dietary and physical therapies that are not usually considered within the realm of conventional therapeutics. Approximately two thirds of the Australian population use CAMs and only around half of this number will discuss their use of these products with their doctor. Clinical use is commonly seen in patients with life-limiting illness, often because they experience a high burden of symptoms. However, it is also the case that many of these therapies do not have demonstrated efficacy, particularly for t

Совпадение в полном тексте источника
… Clinical effects are commonly seen in the combination of cannabidiol and epilepsy therapies. 20 UDP‐glucuronosyltransferase (UGT) enzymes also represent an important pathway of metabolism. … Cannabidiol in anxiety and sleep: a large case series. Perm J 2019; 23: 18–41. 14. Larsen C, Shahinas J. Dosage, efficacy and safety of cannabidiol administration in adults: a systematic review of human trials. J Clin Med Res 2020; 12: 129–41. 15. Australian Clinical Trials. …

Rational drug repositioning for coronavirus-associated diseases using directional mapping and side-effect inference.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen of coronavirus disease 2019 (COVID-19), has infected hundreds of millions of people and caused millions of deaths. Looking for valid druggable targets with minimal side effects for the treatment of COVID-19 remains critical. After discovering host genes from multiscale omics data, we developed an end-to-end network method to investigate drug-host gene(s)-coronavirus (CoV) paths and the mechanism of action between the drug and the host factor in a directional network. We also inspected the potential side effect of the ca

Совпадение в полном тексте источника
… For instance, cannabidiol (CBD), a member of the cannabinoid class of natural products, is an FDA-approved drug for epilepsy treatment. There are four clinical trials of CBD for the treatment of COVID-19. … Cannabidiol (CBD) use in type 2 diabetes: a case report Diabetes Spectr. 34 2021 198 201 10.2337/ds20-0023 34149261 PMC8178711 McLaren W. Gil L. Hunt S.E. Riat H.S. Ritchie G.R.S. Thormann A. Flicek P. Cunningham F. …

Systematic review and network meta-analysis of the efficacy of existing treatments for patients with recurrent glioblastoma.

BackgroundDespite advances in the treatment of cancers over the last years, treatment options for patients with recurrent glioblastoma (rGBM) remain limited with poor outcomes. Many regimens have been investigated in clinical trials; however, there is a lack of knowledge on comparative effectiveness. The aim of this systematic review is to provide an overview of existing treatment strategies and to estimate the relative efficacy of these regimens in terms of progression-free survival (PFS) and overall survival (OS).MethodsWe conducted a systematic review to identify randomized controlled trial

Совпадение в полном тексте источника
… The combination therapy of dose intense TMZ + cannabidiol (CBP) + delta-9-tetrahydrocannabinol (THC) in Short et al. (2017) 34 and Twelves et al. (2017) 35 had the highest median OS with 18.3 months. … BSC, Best supportive care; CBP, cannabidiol; THC, delta-9-tetrahydrocannabinol; PPV, personal peptide vaccination. Figure 3. Forest plot showing trial level outcomes of progression-free survival. …

The efficacy and safety of cannabinoids for the treatment of mental disorders and substance use disorders: a systematic review and meta-analysis.

BACKGROUND: Mental disorders and substance use disorders (SUDs) are among the leading reasons for which the medical use of cannabinoids has … e certainty of evidence for most outcomes was low. Our meta-analysis revealed that a combination of cannabidiol and delta-9-tetrahydrocannabinol reduced cannabis withdrawal symptoms (SMD -0·29, 95% CI -0·57 to -0·02) and weekly grams of cannabis use (-1·00, -1·69 to -0·30) among those with cannabis use disorder, and a reduction in tic severity among those wit …

Molecular Mechanism of Autophagy and Its Regulation by Cannabinoids in Cancer.

Autophagy is a "self-degradation" process whereby malfunctioned cytoplasmic constituents and protein aggregates are engulfed by a vesicle called the autophagosome, and subsequently degraded by the lysosome. Autophagy plays a crucial role in sustaining protein homeostasis and can be an alternative source of energy under detrimental circumstances. Studies have demonstrated a paradoxical function for autophagy in cancer, displaying both tumour suppressive and tumour promotive roles. In early phases of tumour development autophagy promotes cancer cell death. In later phases, autophagy enables canc

Совпадение в полном тексте источника
… Cannabidiol (CBD) and Δ 9 -tetrahydrocannabinol (THC) are the two most abundant phytocannabinoid compounds and are highly recognised for their therapeutic applications in anticancer therapies [ 14 ]. … Special Focus on Cannabidiol. Front. Endocrinol. 2020;11:114. doi: 10.3389/fendo.2020.00114. 15. Biazik J., Ylä-Anttila P., Vihinen H., Jokitalo E., Eskelinen E.L. Ultrastructural relationship of the phagophore with surrounding organelles. …